Selumetinib (AZD6244)

Name: Selumetinib (AZD6244)
Brand: Selleck Chemicals
SKU: S1008
Rating: 5 (542 reviews)

For research use only.

Catalog No.S1008 Synonyms: ARRY-142886

542 publications

Selumetinib (AZD6244) Chemical Structure

CAS No. 606143-52-6

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Selleck's Selumetinib (AZD6244) has been cited by 542 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Nature, 2020, 588(7838):509-514

PubMed: 32927473 ( click the link to review the publication )

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Med, 2019, 25(1):130-140

PubMed: 30510251 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Mater, 2018, 17(4):361-368

PubMed: 29403054 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(4):857-868

PubMed: 29336889 ( click the link to review the publication )

Nat Med, 2018, 24(7):961-967

PubMed: 29808006 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):119-126

PubMed: 27870838 ( click the link to review the publication )

Gastroenterology, 2017, 152(5):1161-1173

PubMed: 27956228 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(2):184-191

PubMed: 26780180 ( click the link to review the publication )

Gastroenterology, 2016, 150(4):918-30

PubMed: 26677984 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Nat Genet, 2015, 47(9):996-1002

PubMed: 26214590 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )
Cancer Cell, 2015, 27(2):240-56

PubMed: 25600339 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1214-29

PubMed: 25256614 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):414-24

PubMed: 22588879 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Genet, 2011, 43(11):1119-26

PubMed: 21946352 ( click the link to review the publication )

Nature, 2010, 16;468(7326):968-72.

PubMed: 21107320 ( click the link to review the publication )

Cancer Res, 2021, canres.1895.2020

PubMed: 33402388 ( click the link to review the publication )

Cancer Lett, 2021, 502:25-33

PubMed: 33440231 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):22

PubMed: 33413561 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)862

PubMed: 33670725 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1408

PubMed: 33808771 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)829

PubMed: 33669371 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Arch Virol, 2021, 166(5):1433-1438

PubMed: 33683474 ( click the link to review the publication )
J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )

In Vivo, 2021, 35(2):721-729

PubMed: 33622865 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)555

PubMed: 33535609 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Cell Biosci, 2021, 11(1):40

PubMed: 33622407 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

Eur Respir J, 2020, 8;2000522

PubMed: 32513782 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Dev Cell, 2020, 52(5):563-573

PubMed: 32032547 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.0448.2020

PubMed: 32605999 ( click the link to review the publication )

Cell Rep, 2020, 31(2):107514

PubMed: 32294432 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 14

PubMed: 32291414 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Oncogene, 2020, 39(15):3218-3225

PubMed: 32051554 ( click the link to review the publication )

Oncogene, 2020, 39(3):703-717

PubMed: 31541192 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )
Cancers (Basel), 2020, 12(7):E1744

PubMed: 32629964 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008307

PubMed: 32069328 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000657R

PubMed: 33124742 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0706

PubMed: 33208393 ( click the link to review the publication )

Development, 2020, 147(23)dev192351

PubMed: 33144395 ( click the link to review the publication )

Mol Cancer Ther, 2020, 13;molcanther11722019

PubMed: 32404410 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 10:1482

PubMed: 33042794 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):21985

PubMed: 33319783 ( click the link to review the publication )

J Biol Chem, 2020, 30 pii: jbc

PubMed: 32358059 ( click the link to review the publication )

Cancer Commun (Lond), 2020, 10.1002/cac2.12092

PubMed: 32888253 ( click the link to review the publication )

J Ethnopharmacol, 2020, 251:112535

PubMed: 31926315 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Transl Oncol, 2020, 14(1):100920

PubMed: 33137541 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Pediatr Blood Cancer, 2020, e28639

PubMed: 32975370 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )
J Chemother, 2020, 32(8):437-444

PubMed: 33052075 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:610

PubMed: 32754596 ( click the link to review the publication )

Cell Rep Med, 2020, 1(8):100131

PubMed: 33294856 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Pathol, 2020, e5503

PubMed: 32613636 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30117-X

PubMed: 32771388 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0609-7

PubMed: 32778845 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158

PubMed: 32034077 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Viruses, 2020, 12(10)E1128

PubMed: 33028008 ( click the link to review the publication )

Arch Virol, 2020, 10.1007/s00705-020-04524-7

PubMed: 31942645 ( click the link to review the publication )

Gastroenterology, 2019, 157(3):823-837

PubMed: 31078621 ( click the link to review the publication )

Gastroenterology, 2019, 156(3):577-581

PubMed: 30391471 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128678

PubMed: 31805013 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:2987

PubMed: 31278260 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5549

PubMed: 31804471 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-4145

PubMed: 31285371 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2494-2510

PubMed: 30862719 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Rep, 2019, 27(3):806-819

PubMed: 30995478 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Oncogene, 2019, 38(18):3402-3414

PubMed: 30643193 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

Stem Cell Reports, 2019,

PubMed: 31231022 ( click the link to review the publication )

Cancer Lett, 2019, 442:53-67

PubMed: 30391781 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31652979 ( click the link to review the publication )

PLoS Pathog, 2019,

PubMed: 30716130 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12812

PubMed: 31323160 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )
Br J Cancer, 2019, 121(9):758-767

PubMed: 31551581 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31766464 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31409052 ( click the link to review the publication )

PLoS Genet, 2019, 15(4):e1008077

PubMed: 30969964 ( click the link to review the publication )

Front Immunol, 2019, 10:2020

PubMed: 31507609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Oncol, 2019, 13(7):1467-1489

PubMed: 30919591 ( click the link to review the publication )

Cancer Sci, 2019, 110(8):2529-2539

PubMed: 31119819 ( click the link to review the publication )

Oncogenesis, 2019, 8(9):50

PubMed: 31492847 ( click the link to review the publication )

Transl Psychiatry, 2019, 9(1):306

PubMed: 31740729 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0274-1

PubMed: 31201369 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(1):L20-L34

PubMed: 30260287 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(1):36-46

PubMed: 31048548 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23123

PubMed: 31571292 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1159

PubMed: 31649535 ( click the link to review the publication )

Int J Oncol, 2019, 54(3):1123-1133

PubMed: 30747223 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(1):349-357

PubMed: 30682205 ( click the link to review the publication )
Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Cell Cycle, 2019, 18(13):1513-1522

PubMed: 31135266 ( click the link to review the publication )

Cell Cycle, 2019, 18(5):596-604

PubMed: 30724698 ( click the link to review the publication )

J Mol Endocrinol, 2019, 63(3):199-213

PubMed: 31416049 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(8):1015-1025

PubMed: 31141756 ( click the link to review the publication )

Pathol Oncol Res, 2019, 25(2):769-775

PubMed: 30706361 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):3569-3575

PubMed: 30867799 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0673-5

PubMed: 31839677 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):201-211

PubMed: 31865182 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Heliyon, 2019, 6(1):e03031

PubMed: 31909243 ( click the link to review the publication )

Sci Transl Med, 2018, 10(450)

PubMed: 30021885 ( click the link to review the publication )

Cell Res, 2018, 28(7):719-729

PubMed: 29795445 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Mol Psychiatry, 2018, 23(2):444-458

PubMed: 28070119 ( click the link to review the publication )

Nat Commun, 2018, 9(1):579

PubMed: 29422527 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5416

PubMed: 30575746 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )
Nat Commun, 2018, 9(1):28

PubMed: 29295999 ( click the link to review the publication )

J Exp Med, 2018, 215(6):1693-1708

PubMed: 29769248 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(19):4854-4864

PubMed: 29945997 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6367-6382

PubMed: 30135148 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Genome Med, 2018, 10(1):90

PubMed: 30482246 ( click the link to review the publication )

Biomaterials, 2018, 156:258-273

PubMed: 29222974 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

Theranostics, 2018, 8(8):2134-2146

PubMed: 29721068 ( click the link to review the publication )

Cancer Res, 2018, 78(6):1444-1456

PubMed: 29321164 ( click the link to review the publication )

Int J Cancer, 2018, 142(2):381-391

PubMed: 28921565 ( click the link to review the publication )

Oncogene, 2018, 37(39):5340-5354

PubMed: 29858603 ( click the link to review the publication )

Cancer Lett, 2018, 414:268-277

PubMed: 29179997 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)

PubMed: 30373214 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Br J Cancer, 2018, 119(6):713-723

PubMed: 30116025 ( click the link to review the publication )

J Clin Med, 2018, 7(5)

PubMed: 29762469 ( click the link to review the publication )

Cancer Discov, 2018, 8(10):1237-1249

PubMed: 30045908 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 49(4):1499-1511

PubMed: 30205377 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )
Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2329-2340

PubMed: 30166401 ( click the link to review the publication )

Br J Haematol, 2018, 182(6):921-924

PubMed: 28771685 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3816-3825

PubMed: 30343534 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30018229 ( click the link to review the publication )

Sci Rep, 2018, 8(1):850

PubMed: 29339801 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

J Biol Chem, 2018, 293(23):9113-9123

PubMed: 29540478 ( click the link to review the publication )

Front Pharmacol, 2018, 8:988

PubMed: 29379440 ( click the link to review the publication )

Mol Cell Endocrinol, 2018, 474:20-34

PubMed: 29428395 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Cell Signal, 2018, 42:11-20

PubMed: 28986121 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2018,

PubMed: 30257106 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Med Sci Monit, 2018, 24:8048-8055

PubMed: 30414267 ( click the link to review the publication )

Med Sci Monit, 2018, 24:3002-3010

PubMed: 29737325 ( click the link to review the publication )

Exp Lung Res, 2018, 44(7):332-343

PubMed: 30676129 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):326-334

PubMed: 29928418 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Nat Methods, 2018, 15(9):732-740

PubMed: 30127506 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):31

PubMed: 29348467 ( click the link to review the publication )
BMC Cancer, 2018, 18(1):542

PubMed: 29739364 ( click the link to review the publication )

Cancer Discov, 2018, 8(11):1458-1473

PubMed: 30185628 ( click the link to review the publication )

Oncotarget, 2018, 9(74):33995-34008

PubMed: 30338041 ( click the link to review the publication )

Gut, 2017, 66(6):1106-1115

PubMed: 27670374 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2081-2090

PubMed: 28504649 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6567-6579

PubMed: 28765329 ( click the link to review the publication )

Neuro Oncol, 2017, 20(6):764-775

PubMed: 29136244 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Int J Cancer, 2017, 140(12):2758-2770

PubMed: 27813079 ( click the link to review the publication )

Cancer Lett, 2017, 408:130-137

PubMed: 28866094 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )

Cancer Discov, 2017, 7(4):369-379

PubMed: 28122867 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

J Mater Chem B, 2017, 5(20):3658-3666

PubMed: 32264054 ( click the link to review the publication )

Sci Rep, 2017, 7:44123

PubMed: 28276530 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 165(Pt B):258-267

PubMed: 27369115 ( click the link to review the publication )

J Biol Chem, 2017, 292(10):3970-3976

PubMed: 28179426 ( click the link to review the publication )

Urol Oncol, 2017, 35(1):32

PubMed: 27692847 ( click the link to review the publication )

Front Physiol, 2017, 7:682

PubMed: 28149280 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Biochemistry, 2017, 56(34):4449-4456

PubMed: 28574701 ( click the link to review the publication )
PLoS One, 2017, 12(9):e0184861

PubMed: 28910386 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170445

PubMed: 28118392 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

ACS Omega, 2017, 2(11):7868-7880

PubMed: 30023564 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Anticancer Res, 2017, 37(2):607-614

PubMed: 28179307 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(7):1069-1077

PubMed: 28353145 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94606-94618

PubMed: 29212253 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28938614 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29113345 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11460-11479

PubMed: 28002790 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Cell, 2017, 168(5):890-903

PubMed: 28162770 ( click the link to review the publication )
J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84697-84713

PubMed: 29156677 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3815-3829

PubMed: 29423085 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):349-64

PubMed: 26657862 ( click the link to review the publication )

Nat Commun, 2016, 7:13615

PubMed: 27897178 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2987

PubMed: 27185371 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6021-6030

PubMed: 27259561 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Cancer Res, 2016, 76(3):675-85

PubMed: 26676756 ( click the link to review the publication )

Cancer Res, 2016, 76(20):6095-6106

PubMed: 27569217 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(12):2475-2484

PubMed: 27498344 ( click the link to review the publication )

Cancers (Basel), 2016,

PubMed: 27187477 ( click the link to review the publication )

J Neurosci, 2016, 36(44):11196-11207

PubMed: 27807163 ( click the link to review the publication )
Cell Death Dis, 2016, 7(10):e2432

PubMed: 27787516 ( click the link to review the publication )

Cell Death Dis, 2016, 7(11):e2456

PubMed: 27809309 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(12):1550-1559

PubMed: 27939899 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1460-71

PubMed: 27196754 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(3):1139-50

PubMed: 26933192 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(12):1204-1216

PubMed: 27655129 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Mol Cancer Res, 2016,

PubMed: 26582713 ( click the link to review the publication )

Sci Rep, 2016, 6:26803

PubMed: 27222248 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27412232 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Biochemistry, 2016, 10.1172/JCI81468

PubMed: 26974155 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155893

PubMed: 27196001 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Leuk Res, 2016, 50:1-10

PubMed: 27626202 ( click the link to review the publication )

Methods Enzymol, 2016, 568:557-80

PubMed: 26795484 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )
Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Integr Biol, 2016, 8(1):73-90

PubMed: 26658688 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7960-9

PubMed: 26799289 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):172-83

PubMed: 26487278 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30907-23

PubMed: 27127178 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27150057 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78396-78411

PubMed: 27623078 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.30

PubMed: 25753158 ( click the link to review the publication )

Nat Commun, 2015, 6:8583

PubMed: 26456302 ( click the link to review the publication )

Nat Commun, 2015, 6:7769

PubMed: 26183061 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0013

PubMed: 26034127 ( click the link to review the publication )
Leukemia, 2015, 29(3):705-14

PubMed: 25102946 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Neuro Oncol, 2015, 10.1093/neuonc/nou369

PubMed: 25712957 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cancer Lett, 2015, 364(1):70-8

PubMed: 25937299 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

J Neurosci, 2015, 35(3):972-84

PubMed: 25609615 ( click the link to review the publication )

J Neurosci, 2015, 35(7):3034-47

PubMed: 25698741 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-267278

PubMed: 25857555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1434-46

PubMed: 25933688 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Front Oncol, 2015, 5:135

PubMed: 26137449 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )
J Transl Med, 2015, 13:210

PubMed: 26139106 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2014.12.007

PubMed: 25624003 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2015, 308(10):E899-911

PubMed: 25805192 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Respir Res, 2015, 16:48

PubMed: 25890309 ( click the link to review the publication )

Int J Oncol, 2015, 47(3):849-56

PubMed: 26179332 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Exp Cell Res, 2015, 332(1):1-10

PubMed: 25637219 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Radiat Oncol, 2015, 10:214

PubMed: 26498922 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 456(3):821-6

PubMed: 25498501 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015, 6(5):3165-77

PubMed: 25638158 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14472-87

PubMed: 25961376 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33397-409

PubMed: 26397223 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26544513 ( click the link to review the publication )
Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(9):1104-18

PubMed: 26105199 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8698-708

PubMed: 25826088 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26317790 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Blood, 2014, 27;124(23):3420-30

PubMed: 25253770 ( click the link to review the publication )

Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(8):5083-96

PubMed: 24526220 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(23):6023-33

PubMed: 25316819 ( click the link to review the publication )

Leukemia, 2014, 10.1038/leu.2014.187.

PubMed: 24912431 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2825-34

PubMed: 24648348 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Oncogene, 2014, 33(33):4236-41

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.392

PubMed: 25435367 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(2):366-73

PubMed: 23924903 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(311):ra12

PubMed: 24497609 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(3):479-84

PubMed: 24422853 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(2):353-63

PubMed: 24398428 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(7):1894-906

PubMed: 24825855 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0452

PubMed: 25349308 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(2):161-73

PubMed: 24243688 ( click the link to review the publication )

Mol Nutr Food Res, 2014, 58(3):528-36

PubMed: 24039193 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Hum Mol Genet, 2014, 23(1):1-11

PubMed: 23933734 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1509-19

PubMed: 24962318 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Neuroscience, 2014, 562:69-74

PubMed: 24412130 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Exp Cell Res, 2014, 327(2):340-52

PubMed: 25128814 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 73(2):259-70

PubMed: 24253175 ( click the link to review the publication )

PLoS One, 2014, 9(2):e83957

PubMed: 24551032 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115068

PubMed: 25500581 ( click the link to review the publication )

PLoS One, 2014, 9(10):e110306

PubMed: 25330306 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97938

PubMed: 24835245 ( click the link to review the publication )

PLoS One, 2014, 9(2):e89646

PubMed: 24586933 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(4):958-61

PubMed: 25218145 ( click the link to review the publication )

Radiat Res, 2014, 182(3):350-62

PubMed: 25117621 ( click the link to review the publication )
Sensors (Basel), 2014, 14(3):5074-117

PubMed: 24625737 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 24962990 ( click the link to review the publication )

Mol Cancer, 2014, 13:154

PubMed: 24941944 ( click the link to review the publication )

Tumor Biol, 2014, 35(10):9759-67

PubMed: 24972969 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Blood, 2013, 121(23):4617-26

PubMed: 23575444 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

Hepatology, 2013, 59(4):1435-47

PubMed: 24242874 ( click the link to review the publication )

J Clin Invest, 2013, 124(1):156-68

PubMed: 24316974 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2155-68

PubMed: 23543055 ( click the link to review the publication )

J Natl Cancer Inst, 2013, 105(1):33-46

PubMed: 23250956 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 10.1038/onc.2013.389

PubMed: 24096476 ( click the link to review the publication )

Cancer Res, 2013, 73(23):7101-10

PubMed: 24121492 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Mol Syst Biol, 2013,

PubMed: 23752269 ( click the link to review the publication )

Cell Rep, 2013, 4(6):1090-9

PubMed: 24055054 ( click the link to review the publication )

Oncogene, 2013, 33(33):4236-41

PubMed: 24336323 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )
Sci Signal, 2013, 5(206):ra3

PubMed: 22234612 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):509-17

PubMed: 23490205 ( click the link to review the publication )

J Neurosci, 2013, 33(10):4280-94

PubMed: 23467345 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Cancer Discov, 2013, 3(4):444-57

PubMed: 23358651 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(6):1131-9

PubMed: 23515613 ( click the link to review the publication )

J Mol Cell Cardiol, 2013, 59:139-47

PubMed: 23510923 ( click the link to review the publication )

Carcinogenesis, 2013, 34(3):638-46

PubMed: 23172668 ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Skelet Muscle, 2013, 3(1):17

PubMed: 23815988 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(20):4051-67

PubMed: 23959801 ( click the link to review the publication )

Exp Cell Res, 2013, 319(12):1732-43

PubMed: 23701950 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

Oncol Rep, 2013, 29(2):812-8

PubMed: 23229346 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 500(7461):222-6

PubMed: 24349570 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68817

PubMed: 23935891 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(9):1496-506

PubMed: 24036604 ( click the link to review the publication )

University of Southampton, 2013, University of Southampton

PubMed: ( click the link to review the publication )

Nature, 2013, 504(7478):138-42

PubMed: 24185007 ( click the link to review the publication )

Cancer Res, 2013, 73(15):4840-51

PubMed: 23737487 ( click the link to review the publication )
Gut, 2012, 61(2):202-13

PubMed: 21813469 ( click the link to review the publication )

J Clin Invest, 2012, 122(7):2637-51

PubMed: 22653055 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Oncogene, 2012, 31(27):3277-86

PubMed: 22020336 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Cardiovasc Res, 2012, 93(2):311-9

PubMed: 22068161 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(2):317-28

PubMed: 22188813 ( click the link to review the publication )

Endocr Relat Cancer, 2012, 19(1):29-38

PubMed: 22109971 ( click the link to review the publication )

Carcinogenesis, 2012, 33(5):956-61

PubMed: 22327936 ( click the link to review the publication )

Am J Pathol, 2012, 180(6):2462-78

PubMed: 22546478 ( click the link to review the publication )

J Biol Chem, 2012, 287(50):41797-807

PubMed: 23076151 ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2012, 304(5):C431-9

PubMed: 23255578 ( click the link to review the publication )

Neuroscience, 2012, 206:224-36

PubMed: 22280975 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(1):43-9

PubMed: 22336587 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29622

PubMed: 22253748 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Aging, 2012, 4(11):803-822

PubMed: 23362510 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Biomaterials, 2011, 32(35):9197-206

PubMed: 21899882 ( click the link to review the publication )
Mol Syst Biol, 2011, 7:489

PubMed: 21613978 ( click the link to review the publication )

J Invest Dermatol, 2011, 132(2):356-64

PubMed: 21993556 ( click the link to review the publication )

J Clin Endocrinol Metab, 2011, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(5):545-52

PubMed: 21478267 ( click the link to review the publication )

Endocrinology, 2011, 152(7):2589-98

PubMed: 21521747 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Biol Reprod, 2011, 85(1):42-50

PubMed: 21349822 ( click the link to review the publication )

PLoS One, 2011, 6(12):e28973

PubMed: 22194965 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Brit J Haematol, 2010, 149(4):537-49

PubMed: 20331454 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Nature, 2010, 468(7326):973-7

PubMed: 21107323 ( click the link to review the publication )

P Natl Acad Sci USA, 2009, 106(48):20411-6

PubMed: 19915144 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

First MEK inhibitor being tested in Phase II clinical trials.

Targets

MEK1 ^[1] (Cell-free assay)	MEK1 ^[13] (Cell-free assay)	MEK2 ^[13] (Cell-free assay)
14 nM	99 nM(Kd)	530 nM(Kd)

In vitro

AZD6244 is not competitive with ATP and inactivates the ERK1/2 phosphorylation with IC50 concentrations below 40 nM. AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90^RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. AZD6244 has little effects on the p38, c-Jun-NH₂-kinase, phosphatidylinositol 3-kinase, and MEK5/ERK5 pathways. ^[1] AZD6244 is sensitive to Raf mutations in breast cancer cell lines and Ras mutations in NSCLC cell lines. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
CHP-212	M1zZTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{TGWGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yMEOxOVMh\|ryPLh?=	NHzEWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H9	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIWzRlNKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlAzOjh6IN88UU4>	NUfwcopnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HL-60	NFixXJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlAzPDV7IN88UU4>	NVviUlByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NOMO-1	MmXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGrsO4pKdmirYnn0bY9vKG:oIHj1cYFvKE6RTV:tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yM{G5O{DPxE1w	MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DU-4475	MoDFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV\SPIc4UW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkCzN\|Y4KM7:TT6=	NF72U4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
M14	MlfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWTJcohq[mm2aX;uJI9nKGi3bXHuJG0yPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wN\|Y5QSEQvF2u	M{H5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-144	NWL0PYxLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1jmS2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjB6OUC1JO69VS5?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-N-AS	NXvGXplsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXvJdGN[UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWFUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkC5Nlg{KM7:TT6=	M4XYdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LB2518-MEL	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVPOcWN7UW6qaXLpeIlwdiCxZjDoeY1idiCOQkK1NVguVUWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlA6Ozh{IN88UU4>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
C32	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHj6Ro9KdmirYnn0bY9vKG:oIHj1cYFvKEN\|MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xQTh{MzFOwG0v	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BHT-101	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOTB4OUOg{txONg>?	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KY821	NUT6UFh[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3XvVGlvcGmkaYTpc44hd2ZiaIXtZY4hU1l6MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOTB5MUig{txONg>?	NX34O4tpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CP50-MEL-B	M3i5R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNRPTBvTVXMMWIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUK3PVQh\|ryPLh?=	NEPH[209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MEL-HO	MkPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1GVC2KTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yOzh6NDFOwG0v	NXjJUZpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EoL-1-cell	NY\HfJFiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUS0O\|Yh\|ryPLh?=	NGHGPVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
DOK	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX;Pc5l7UW6qaXLpeIlwdiCxZjDoeY1idiCGT1ugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOTR5MEig{txONg>?	NV3WfItrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SH-4	NFe2VHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEDyXpdKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOTZ4NEig{txONg>?	NWTpO2dXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BPH-1	NV;wToh1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlvuTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yQDJ\|MTFOwG0v	M2O3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HuP-T4	M2\kfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3;yR2lvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjF7NUOyJO69VS5?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KU812	NXjRXJVCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEPxXFZKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJzMU[4JO69VS5?	NUntbGF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A549	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1P0dGlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zOTRzMzFOwG0v	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HTC-C3	MmrzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhVSy2FMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zOTR4MTFOwG0v	NGfOOIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A101D	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmTRTY5pcWKrdHnvckBw\iCqdX3hckBCOTBzRDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zPDB\|MzFOwG0v	NYrhSo91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ONS-76	NV;jWW9FT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVjzZmFvUW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO\|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMkS0OVMh\|ryPLh?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RKO	M17vcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmHJTY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNlQ5OzhizszNMi=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
WM-115	M{fufmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH\mWmZKdmirYnn0bY9vKG:oIHj1cYFvKFePLUGxOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{Nke1OEDPxE1w	MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2998	Ml7oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MorpTY5pcWKrdHnvckBw\iCqdX3hckBJS0N{OUm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJ4OUC3JO69VS5?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
C2BBe1	NUn4N2p2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkTXTY5pcWKrdHnvckBw\iCqdX3hckBEOkKEZUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjd{NUmg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RVH-421	NXrXUpNUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2\pOmlvcGmkaYTpc44hd2ZiaIXtZY4hWl[KLUSyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{N{mzPUDPxE1w	NFPwRmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H-EMC-SS	NUfD[JQyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHr2NGhKdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkK5NFk6KM7:TT6=	MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ML-2	M1jTSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNlk{PjNizszNMi=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW620	NHm5TlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1n5fGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzB{MjFOwG0v	NGjqXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
UACC-257	Ml\zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFLrSYlKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkOyNVg1KM7:TT6=	M2\KclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
AsPC-1	M2Dj[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWXJcohq[mm2aX;uJI9nKGi3bXHuJGF{WENvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4{OjR\|OTFOwG0v	NFfJPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-39	MlfCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWW2RXhLUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwM{OyNlYh\|ryPLh?=	M2K3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
COLO-679	Mk\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NELvTYpKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkO0NVE6KM7:TT6=	M{iyc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H747	NFTEXItIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NITlWVNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkO1NFk5KM7:TT6=	NXPh[5c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1437	NUDpXVd1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVG0TpF{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE1OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuN\|UzQDVizszNMi=>	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
PSN1	M3u5SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4C1WGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4{PjZyOTFOwG0v	MkG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NKM-1	NWPtNI1lT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWOzdGJRUW6qaXLpeIlwdiCxZjDoeY1idiCQS12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|OEW4JO69VS5?	M4LPZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MZ2-MEL	NYXid\|hsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEjPS\|hKdmirYnn0bY9vKG:oIHj1cYFvKE2cMj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwM{m0N\|ch\|ryPLh?=	NXuySYpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SK-MEL-2	M4nZNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mm\JTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC52MEWwOkDPxE1w	M3ziUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LAMA-84	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4\l[mlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC52NU[yNkDPxE1w	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
U-266	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{Xvd2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPDh5N{Sg{txONg>?	NHTObVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RCM-1	M{jFe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWrJcohq[mm2aX;uJI9nKGi3bXHuJHJEVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlQ6Ozh3IN88UU4>	NYPSRnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EM-2	M{[2Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVLGbVZTUW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjVzMUe1JO69VS5?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Mewo	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NI\CW2ZKdmirYnn0bY9vKG:oIHj1cYFvKE2nd3:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTJzMEGg{txONg>?	NYTMVop5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-741	NYDuT4E3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3\lb2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwNUOxNVkh\|ryPLh?=	NEn3Vlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ACN	NULkW2xDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGFEViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD61OlY6KM7:TT6=	NXjGfndMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MV-4-11	NH3IcpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1S2WGlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC53N{W0N{DPxE1w	NGTtdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW780	M4DLeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUnOVmpFUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC54Nk[zOEDPxE1w	MlHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
JVM-3	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFrZWHVKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjdyME[g{txONg>?	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RPMI-8226	Mn63S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1zvV2lvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke0JO69VS5?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HO-1-N-1	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEOxNYZKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke0NFUzKM7:TT6=	M3r6Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BV-173	NXz3[oVJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mke5TY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPzR6MEKg{txONg>?	NH\zb2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H2291	NILveJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnLHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyPVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{[xO\|Mh\|ryPLh?=	M3\DTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-MEL-30	M3jjZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mlf6TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{ixO\|Eh\|ryPLh?=	M1m1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LB2241-RCC	M4PuTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkDFTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke4PVkyKM7:TT6=	NHfROpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LOXIMVI	M2T4dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVSzPXprUW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLki1PFU1KM7:TT6=	NHy2Npk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HT-29	Moj4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn\jTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45PzNzOTFOwG0v	NF[2Vo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KG-1	NWXyRpJVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1Xib2lvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45QTV2NzFOwG0v	NVrkVYFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW954	NVzLUmJmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn\jTY5pcWKrdHnvckBw\iCqdX3hckBUXzl3NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45QTZ2NTFOwG0v	NVKxbno1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MIA-PaCa-2	M4q1PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1nheWlvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD64PVc3QCEQvF2u	NXm0PIhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCE-T	MnjZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4PO[mlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQTdzM{Gg{txONg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HN	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkCwNlU4KM7:TT6=	MkW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LCLC-97TM1	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4nMb2lvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz25O3ROOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6wN\|E6OSEQvF2u	MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NB69	M4foOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkLXTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlA2OzlizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LoVo	MnmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNFYzOzFizszNMi=>	NV;RR\|dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCT-116	NYjLeIJHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIXYO3RKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwME[0N\|Eh\|ryPLh?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
AGS	NWHZfoN7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVfJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6xNVg{OSEQvF2u	NXH6fYxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H292	M3;yRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1OydWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwMUG5PUDPxE1w	Mn72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	NVSzb5BpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVLqdGMyUW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOTV6OUmg{txONg>?	NHnvXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
D-263MG	MkPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2\ObGlvcGmkaYTpc44hd2ZiaIXtZY4hTC1{NkPNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zOEC5OEDPxE1w	NVGyNpc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-792	NHH0XYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\SSXpKUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT6xPFY{KM7:TT6=	M2DORlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HSC-3	M{PCTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFLyOVlKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjF6OEKzJO69VS5?	NYnwc\|JVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NUGC-3	NVfYPY9ST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1XwdmlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjJyM{e5JO69VS5?	NFLnS\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW872	Mmr1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2rZbWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOjZ6NUWg{txONg>?	NWDNS4xyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuCCT1	NX7RWYViT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGXpfHFKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5{OUm2JO69VS5?	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
QIMR-WIL	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXfJcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjN2M{i0JO69VS5?	NEPkbmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H2087	M1HGbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn3aTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwM{e1NUDPxE1w	MnvnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LS-513	NFm1O25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWn2XWpPUW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNEKxPVEh\|ryPLh?=	M13DXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-54	M2LPUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU41QTNzNDFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A204	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuOVE3PjdizszNMi=>	NEXuSHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-62	NHPKTmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEjHZ5BKdmirYnn0bY9vKG:oIHj1cYFvKEODTD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS53MkK5NkDPxE1w	NIDTXIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-33	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mm\PTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPTR4OUSg{txONg>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
COLO-678	MmLvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{DQSGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O\|gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNkKzPFIh\|ryPLh?=	NGfjWWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MEG-01	NWnaRnh6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmfRTY5pcWKrdHnvckBw\iCqdX3hckBOTUdvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPjJ7NUmg{txONg>?	Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HAL-01	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEjaSXdKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS54OUW3JO69VS5?	NXnBR2VxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OAW-28	NUjTdWFsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJG9CXy1{ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU44PDN7NzFOwG0v	NY\rSpFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-SNU-1	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{ThZmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLke3NlQ{KM7:TT6=	M3LtOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BHY	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnfOTY5pcWKrdHnvckBw\iCqdX3hckBDUFliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuPFExOzRizszNMi=>	MlniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EGI-1	M1XDe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmexTY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU45Ojh{IN88UU4>	Ml;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BB65-RCC	NXLIcZoxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXvGNWhrUW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT64N\|g2PSEQvF2u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GAK	MnTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkLMTY5pcWKrdHnvckBw\iCqdX3hckBISUtiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuPVA1PzVizszNMi=>	NVu2ZXJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SK-MEL-3	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGPlemFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkm1NFc4KM7:TT6=	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KARPAS-45	NIq4TVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml;4TY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwMEiyOFgh\|ryPLh?=	NWfL[ZFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BCPAP	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGf2[3VKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjF{N{Sg{txONg>?	NFvzNWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RT-112	NXHCNnZzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk4zPjB2NjFOwG0v	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-HEP-1	NEnTcYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGHQU3ZKdmirYnn0bY9vKG:oIHj1cYFvKFONLVjFVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkK5NFQ5KM7:TT6=	M4HRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Ca9-22	M3yzNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1X6TWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjN5Nk[3JO69VS5?	NGPRTFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OS-RC-2	M4nLXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX;MfFdNUW6qaXLpeIlwdiCxZjDoeY1idiCRUz3SR{0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkSwN\|M4KM7:TT6=	NIH4bHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BFTC-905	NFHE[3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHTX[oZKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkSyN\|EzKM7:TT6=	MnL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HT-1080	MmLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4HMbWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi52M{CxJO69VS5?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC2218	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHn2TXVKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwNEi0PFch\|ryPLh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KM12	NEnLS4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3;JR2lvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk42Ozl4MTFOwG0v	NHnLWW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NB5	NEnMN5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFj0XI5KdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk42PjZ2MTFOwG0v	NV:xcpI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BB30-HNC	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVHsdHhYUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj63NVI6OyEQvF2u	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H460	MkDyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUnMR5FTUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj64NFI4PCEQvF2u	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LAN-6	M3nIUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoH4TY5pcWKrdHnvckBw\iCqdX3hckBNSU5vNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk45Ojh4NzFOwG0v	NUHYS5hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EW-3	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mnv0TY5pcWKrdHnvckBw\iCqdX3hckBGXy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlkzPTB3IN88UU4>	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CAL-27	Ml76S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmnQTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvODZzMUig{txONg>?	NYL1N3hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COR-L105	NEGxWIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkLKTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy5zM{S2NkDPxE1w	M3[5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EFO-21	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3Hi[2lvcGmkaYTpc44hd2ZiaIXtZY4hTU[RLUKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjF7MkK2JO69VS5?	MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MZ1-PC	MoPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{4{OTZyNTFOwG0v	M17YXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EFO-27	NEXHdo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4DFRmlvcGmkaYTpc44hd2ZiaIXtZY4hTU[RLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjN{NkGyJO69VS5?	MlnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HPAF-II	Ml3WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkP4TY5pcWKrdHnvckBw\iCqdX3hckBJWEGILVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjN\|N{K5JO69VS5?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KU-19-19	M1HzVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkO4TY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy52MUm1NUDPxE1w	NFnBd5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	NHXl[pBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy54MUS0PUDPxE1w	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LS-123	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmHjTY5pcWKrdHnvckBw\iCqdX3hckBNWy1zMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvPjF6M{Gg{txONg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
769-P	MnrlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkjqTY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{44PDJ4IN88UU4>	M17kWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SJSA-1	NFzMVldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUXiUGZiUW6qaXLpeIlwdiCxZjDoeY1idiCVSmPBMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwN{ixOFYh\|ryPLh?=	NGTZRmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-LU-1	MkTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoSxTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njh4MkOxJO69VS5?	M1O1blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A3-KAW	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVnEUXhtUW6qaXLpeIlwdiCxZjDoeY1idiCDMz3LRXch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwOUGwOVUh\|ryPLh?=	NF6ydWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LB996-RCC	M3f4TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGLXcm9KdmirYnn0bY9vKG:oIHj1cYFvKEyEOUm2MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMz65OVA1OyEQvF2u	NFLqZlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SN12C	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIPuPYhKdmirYnn0bY9vKG:oIHj1cYFvKFOQMULDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njl3NUezJO69VS5?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
COR-L23	NX7NZ3lDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NE\OSIFKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwOUW2Olkh\|ryPLh?=	NIew[\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
VM-CUB-1	NXT2fYV[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnvVTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy57NkmzNUDPxE1w	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RXF393	NYnMd2xFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlnjTY5pcWKrdHnvckBw\iCqdX3hckBTYEZ\|OUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvODF3OUGg{txONg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MOLT-13	Ml3qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{TzOWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5yM{SxPUDPxE1w	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GCT	NFvRNJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\FelkxUW6qaXLpeIlwdiCxZjDoeY1idiCJQ2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOTB2NEKg{txONg>?	NV3qOJVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1990	M2rTb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mom4TY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOTZ4MkKg{txONg>?	NEO5eIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RD	MnLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoHLTY5pcWKrdHnvckBw\iCqdX3hckBTTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND6xPVE{QCEQvF2u	M3vZblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HOP-92	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUfIUXZIUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMkCwPVMh\|ryPLh?=	NITI[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ME-180	M3TabWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGjqdIlKdmirYnn0bY9vKG:oIHj1cYFvKE2HLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5{NUi1PUDPxE1w	NHfSU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MZ7-mel	NF;C[JpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1bPy2vZXygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPDV{NkWg{txONg>?	M4TMTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAKI-1	NIryU3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3\6[2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjR4MEW3JO69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
YKG-1	M2DTOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1XrNmlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPTN2MkGg{txONg>?	NHixeJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
PANC-03-27	Mny2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXLlXGJGUW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0MlU{QTJ7IN88UU4>	NY\5RoFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A4-Fuk	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkXYTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPTR{MEKg{txONg>?	MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H441	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{PLR2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNU[zOFIh\|ryPLh?=	NGTtUZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BxPC-3	NILuOmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYLJcohq[mm2aX;uJI9nKGi3bXHuJGJ5WENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE43PTl5NjFOwG0v	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ES3	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoK1TY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuOlkyPzNizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GP5d	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGdRPWRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuO\|g2PTNizszNMi=>	NITZOZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-85-1	NWrTbHIzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEXyV4ZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD24OU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Lke5OFIh\|ryPLh?=	NY\PO41kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EPLC-272H	NW\QRoZET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlfXTY5pcWKrdHnvckBw\iCqdX3hckBGWEyFLUK3Nmgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwOEG2PVgh\|ryPLh?=	NYjORWVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuP-T3	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2HNOmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Njh{NEC4JO69VS5?	NXXmWFAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1710	NX3qdm1uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEn1Z\|FKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS5yM{W0PUDPxE1w	MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-8	Mn7QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnPHTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlA3QTFzIN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TE-12	MoO4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoewTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU4yOzdyMzFOwG0v	NWD3Nol6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1573	MoruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXuwRpNZUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuNlczOzhizszNMi=>	Mo\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW1417	NXG1WXNGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mk\QTY5pcWKrdHnvckBw\iCqdX3hckBUXzF2MUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvOjd\|OUig{txONg>?	NX7RbXFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CHL-1	MkPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFe2SZBKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjNzOUmg{txONg>?	NUTpTmlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
Calu-6	NWn2c5djT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU41Ojl{NzFOwG0v	NUTDOnE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MDA-MB-231	NWTDUYVbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3PHNGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNT61OlUzOyEQvF2u	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SCC-25	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{fEZWlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUK1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2Njl5MUKxJO69VS5?	NViwNpNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
639-V	NUe0UodzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1f0S2lvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFYvOTJ7M{Og{txONg>?	Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
D-502MG	NE\VXZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYjlZ\|VGUW6qaXLpeIlwdiCxZjDoeY1idiCGLUWwNm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB4LkG3OlU6KM7:TT6=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
PANC-10-05	NETBe\|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mk\tTY5pcWKrdHnvckBw\iCqdX3hckBRSU6FLUGwMVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB4LkKwNVgyKM7:TT6=	MmrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M4XKO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\QV\|RMUW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi5{N{C5OEDPxE1w	NVnYSpo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NB10	M3zzcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXrJe3dWUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjN{NUOzJO69VS5?	NXPCfoN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MSTO-211H	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3fvS2lvcGmkaYTpc44hd2ZiaIXtZY4hVVOWTz2yNVFJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB4LkSwNFgh\|ryPLh?=	M1\pU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1651	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi54NUOyPEDPxE1w	MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
697	M1jGTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmnwTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uOlc{QTdizszNMi=>	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC70	MlvBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkfkTY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk43QDh4NTFOwG0v	MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW1116	MnzGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4HEOmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjhzMkm3JO69VS5?	M37lWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-MES-1	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3Njh2OEig{txONg>?	MmPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GCIY	NIXORWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlLCTY5pcWKrdHnvckBw\iCqdX3hckBIS0m\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlkyQTZ{IN88UU4>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GMS-10	M4nFT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX73SWV[UW6qaXLpeIlwdiCxZjDoeY1idiCJTWOtNVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMEe3OVUh\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1092	MnHFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFHMNZFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNz6xOVM{PCEQvF2u	M3vJVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CFPAC-1	NID3cXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3rOR2lvcGmkaYTpc44hd2ZiaIXtZY4hS0[SQVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy5{MkGwNUDPxE1w	M4\jb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TK10	NUH1PVg1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYLxZW9LUW6qaXLpeIlwdiCxZjDoeY1idiCWS{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjN3NUi3JO69VS5?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
FADU	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnexTY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC3MlUxQTNizszNMi=>	NUfMOmpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
8305C	M3XKNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml\UTY5pcWKrdHnvckBw\iCqdX3hckA5OzB3QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{45PTN3NTFOwG0v	NYP6SIRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DK-MG	NWLi[5JNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYXBW5JGUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy57NEmzO{DPxE1w	M1XtSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BFTC-909	NHHLWZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3TH[WlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwOUe4N\|Yh\|ryPLh?=	Ml\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
IGR-1	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGlIWi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlE5ODVzIN88UU4>	NYrYc3dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MDA-MB-361	MluwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVLBUpJRUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlE5OjRizszNMi=>	M4XKS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KYSE-150	MmPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIfP[ItKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB6LkKxPVM4KM7:TT6=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DB	MoK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB6LkO2PVA2KM7:TT6=	Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NH-12	M4HYUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHnXdmhKdmirYnn0bY9vKG:oIHj1cYFvKE6KLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjR{N{O2JO69VS5?	NW\oW3pWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CTV-1	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIe0XJZKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjR\|M{O3JO69VS5?	NEP2OWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A498	NVL4bY44T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIDmWpJKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvPzh2N{Wg{txONg>?	NVyzbHM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LS-1034	MnfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVTjXXA5UW6qaXLpeIlwdiCxZjDoeY1idiCOUz2xNFM1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB6Lkm2OFY1KM7:TT6=	MkPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
FTC-133	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1jnZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTlSFLUGzN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC57OES1PUDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TGBC11TKB	NUi1SnpmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH22bWRKdmirYnn0bY9vKG:oIHj1cYFvKFSJQlOxNXRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOT6xNFg{PiEQvF2u	MnXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-MEL-1	MoHIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXfLXWVDUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOT6xPVE{PiEQvF2u	NHLr[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RPMI-7951	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXzzeI1RUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuNlUzODFizszNMi=>	NGjtRoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GT3TKB	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEHwWJZKdmirYnn0bY9vKG:oIHj1cYFvKEeWM2TLRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS5\|N{SwN{DPxE1w	MofDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW962	NYfUU49uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHHlOWJKdmirYnn0bY9vKG:oIHj1cYFvKFOZOU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA6NjV{M{K1JO69VS5?	NH;xbYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
T-24	NXH6dmE2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWTpfHZ{UW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA6NjZ3OEC3JO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DBTRG-05MG	M{S3U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4HXXGlvcGmkaYTpc44hd2ZiaIXtZY4hTEKWUletNFVOTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOT63OVY3PiEQvF2u	NWfq[Yw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
G-401	M4\Rb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIW1fI9KdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC5yN{O5JO69VS5?	NV;BVHJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RS4-11	M{DD[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MomxTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjJ5OUGg{txONg>?	NXvpSG12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KGN	M1rlNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlSxTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlQxPDZizszNMi=>	NIPtbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
786-0	NH3oc\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTBSHJ5UW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEG2OkDPxE1w	MonSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EW-18	M{nJbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\wdGF4UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEO2OkDPxE1w	MlSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DEL	NHnOcVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4L1c2lvcGmkaYTpc44hd2ZiaIXtZY4hTEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE42PDVizszNMi=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HuH-7	MlX6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGh2UC15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE42PzB3IN88UU4>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MG-63	MkL2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2PzdWlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjd\|M{Og{txONg>?	MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A253	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MljiTY5pcWKrdHnvckBw\iCqdX3hckBCOjV\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE44QTB{IN88UU4>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TGW	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1zrO2lvcGmkaYTpc44hd2ZiaIXtZY4hXEeZIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE44QTN5IN88UU4>	NH;Re2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HH	NXLUdI9LT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHnYTlBKdmirYnn0bY9vKG:oIHj1cYFvKEiKIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE45ODZ{IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LS-411N	MlK3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWHZdYlyUW6qaXLpeIlwdiCxZjDoeY1idiCOUz20NVFPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD64NlQ1KM7:TT6=	M4[w[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2347	MoLJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwOESzO{DPxE1w	MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LU-65	NGrqRXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2HqOGlvcGmkaYTpc44hd2ZiaIXtZY4hVFVvNkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjl{Mk[g{txONg>?	NVrnXGJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TE-11	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFHtNXhKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5yMkWg{txONg>?	NWDzbWlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SBC-1	M2D4OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHnKbmRKdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5zMEOyJO69VS5?	NV3Y[JJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TGBC24TKB	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoH2TY5pcWKrdHnvckBw\iCqdX3hckBVT0KFMkTUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkGxPEDPxE1w	MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ECC10	NUX6O3RsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVESzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU4zOjh\|IN88UU4>	NFHpWZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GR-ST	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIO2NpVKdmirYnn0bY9vKG:oIHj1cYFvKEeULWPUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5{Nkig{txONg>?	NXL4eYluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H720	NX3jS\|c5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEXoZWhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT6zPVc4KM7:TT6=	NUK3RoFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
VA-ES-BJ	M1u4[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M374U2lvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkW1NVMh\|ryPLh?=	M3HxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MOLT-16	M1L1SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYLUTVJIUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6xNVYyKM7:TT6=	M{\lNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KYSE-140	Mn7qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWX6OllOUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE1OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuNVU6PiEQvF2u	NHvVV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SCC-4	M3;IR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnn1TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvOjRizszNMi=>	M2C0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1155	NEPUZWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXPtV\|F2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEyPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGyMlMxOTdizszNMi=>	M1fZU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
OCUB-M	NGLQOIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYTTV\|NmUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkOxPFkh\|ryPLh?=	M4\XfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MN-60	MlG1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoDRTY5pcWKrdHnvckBw\iCqdX3hckBOVi14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvOzd\|MjFOwG0v	NUnBVlRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RO82-W-1	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NInsSGpKdmirYnn0bY9vKG:oIHj1cYFvKFKROEKtW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMj6zPFc6KM7:TT6=	M{TJTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KOSC-2	MoPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvPTVyODFOwG0v	M3\3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
L-363	Ml7hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1fk[WlvcGmkaYTpc44hd2ZiaIXtZY4hVC1\|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjV7MkWg{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H661	M4\kXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXnyXpVOUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuPFU5PyEQvF2u	NH[4Z449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KYSE-450	M2XvXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV[1ZotmUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVQ2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUOuNFM6PiEQvF2u	NUnkcFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TI-73	NYWxNVBUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGi1TYJKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy5yNESg{txONg>?	Mof1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KNS-81-FD	M3HpcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M13UcWlvcGmkaYTpc44hd2ZiaIXtZY4hU06VLUixMWZFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMz6wO\|Q5KM7:TT6=	NXqySlcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC1954	MmrES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjJ5OEOg{txONg>?	MofmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A427	M4PoZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGzMlY3QDlizszNMi=>	NIjOUlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MOLT-4	NEL0O4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlrITY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{Njh3M{Gg{txONg>?	NUPqbVlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
U-118-MG	Mm[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGPuNlFKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMz64O\|AzKM7:TT6=	M2DncVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SF126	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkHBTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVMvQTF4NTFOwG0v	M1jIfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SF539	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxN{46PDd2IN88UU4>	NGi3PHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Daoy	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG0MlQ6PzlizszNMi=>	NYPlVmpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DoTc2-4510	NFi0PYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXf3VIVVUW6qaXLpeIlwdiCxZjDoeY1idiCGb2TjNk01PTFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOE42OTd3IN88UU4>	M3u1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TYK-nu	MnvDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M13vbWlvcGmkaYTpc44hd2ZiaIXtZY4hXFmNLX71JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC53NjFOwG0v	MkXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CGTH-W-1	M3G2SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkfwTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTRwOES4N{DPxE1w	NX\kN2FFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuO9	NFTWN2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGSweFdKdmirYnn0bY9vKG:oIHj1cYFvKEi3T{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE2NjB4MzFOwG0v	NH61VpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EW-16	NY[4dIl5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU4xQTR7IN88UU4>	NGDxSVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H630	M4\Gcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1PlPWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2N\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF3LkG2NVMh\|ryPLh?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CAL-12T	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml\nTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMULUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPS5\|M{Gg{txONg>?	Ml;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-5	Mn3zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmfTTY5pcWKrdHnvckBw\iCqdX3hckBVTS13IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU43OTN\|IN88UU4>	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
U251	M{TuSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{noO2lvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVUvPzN6MzFOwG0v	NFnpXm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BB49-HNC	M3H2T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUDYZ25VUW6qaXLpeIlwdiCxZjDoeY1idiCEQkS5MWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMU[uOVA3KM7:TT6=	NFz0dWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OCI-AML2	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWDJcohq[mm2aX;uJI9nKGi3bXHuJG9EUS2DTVyyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPi54NkWg{txONg>?	NUPSV20yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KINGS-1	M2ixZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1\1V2lvcGmkaYTpc44hd2ZiaIXtZY4hU0mQR2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwNkmxPEDPxE1w	NWfjbVI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
D-566MG	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2XZeWlvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwN{K2NkDPxE1w	NWm2THBNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
P30-OHK	NUT6dZVlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4jDNWlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwOUC2PEDPxE1w	NYrCSYV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
GAMG	NIjDVYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH3pO21KdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE3Njl{NEOg{txONg>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC1419	NVjlSYFrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGrFfpJKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF5Lk[xN\|kh\|ryPLh?=	NGj1UoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SNU-C2B	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3\6TGlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLVOyRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTdwN{O3O{DPxE1w	M4nIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MHH-NB-11	Mo\HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml3rTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvTlKtNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6LkGzPFMh\|ryPLh?=	NYThZ3hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-684	Mn\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWXXeY1qUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUiuNlM5OyEQvF2u	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
OC-314	Ml;IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnHYTY5pcWKrdHnvckBw\iCqdX3hckBQSy1\|MUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5NjN3ODFOwG0v	M3XGRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Becker	Ml3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3jVVmlvcGmkaYTpc44hd2ZiaIXtZY4hSmWla3XyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQC52NkKzJO69VS5?	M3izbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1623	M2LBcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVT4ZWo4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3OjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG4MlY{PjhizszNMi=>	M3K3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
IGROV-1	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIrpVHdKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6Lk[1OVkh\|ryPLh?=	NUPvU\|ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HSC-2	MlHhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWr2TlBVUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOThwOUW3O{DPxE1w	M3vmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RMG-I	MmfuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{L0TWlvcGmkaYTpc44hd2ZiaIXtZY4hWk2JLVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6NjF\|M{ig{txONg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CAL-120	MkKwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmDnTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMUKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS5{M{W0JO69VS5?	MnjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GB-1	NVWyWYtQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGTNNWlKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6Njd2NESg{txONg>?	NGfSPXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LU-139	M2K1cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXvwV49[UW6qaXLpeIlwdiCxZjDoeY1idiCOVT2xN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJyLkG4NVYh\|ryPLh?=	M3L1U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-1376	M4noRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mk\wTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zM{e2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOC53N{eyJO69VS5?	NIDQe3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW982	MkLHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXfSSpBYUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjBwNkizO{DPxE1w	M2Lt[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-N-FI	NEfDfHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIyNjB6OE[g{txONg>?	NFn2[JE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SCC-9	MorGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mm\ETY5pcWKrdHnvckBw\iCqdX3hckBUS0NvOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlEvOTRyOTFOwG0v	NIe2[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW756	MkKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NE\6ZY5KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS5{MUW2JO69VS5?	NEDRXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW948	M4TGTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2rmVGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIyNjV{M{[g{txONg>?	Mn3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW1573	M4DPTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHy0OY9KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjFwOEO0OUDPxE1w	M3ro[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1792	M4rRfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnrNTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJzLki1OlUh\|ryPLh?=	NH24eoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BE-13	NFz0NHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo\4TY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlIvPTh5MzFOwG0v	NX7vW3UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SK-OV-3	NIThSWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGXjSZdKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ{LkezPFgh\|ryPLh?=	M3XBW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
PA-1	NUHJWHN3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXfJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKyMlg4OTJizszNMi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1693	NF\qcFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NY\1eYJlUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3QTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKyMlk{OTNizszNMi=>	NHvnWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
no-10	MmrMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnKzTY5pcWKrdHnvckBw\iCqdX3hckBvdy1zMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvOzV6ODFOwG0v	MlXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
JVM-2	M1vtcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoX1TY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvPDF2NzFOwG0v	NWPySmtSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SK-NEP-1	MmHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NY\kN4ZNUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkOuOVIxPSEQvF2u	NInsWZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
PC-3	NVf4fHdFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlzHTY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyN{42PzJ{IN88UU4>	NF;0cIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
U-2-OS	NU\YSGZCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlvXTY5pcWKrdHnvckBw\iCqdX3hckBWNTJvT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI{Njh2Nkmg{txONg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NBsusSR	NIfvPFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGfndYxKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkGwOlIh\|ryPLh?=	NVfXR4lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EW-13	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUHXe3B2UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjRwMUO5PEDPxE1w	NXHsZ5dvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BT-20	MoLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkTjTY5pcWKrdHnvckBw\iCqdX3hckBDXC1{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlQvPzF5ODFOwG0v	Mkn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MS-1	NFe1VoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWWwOZN7UW6qaXLpeIlwdiCxZjDoeY1idiCPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS5yNEm4JO69VS5?	MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC1187	M4PMZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NI\MZZFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GxPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ3LkS0OVEh\|ryPLh?=	M{XxO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-1	MoDRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnrwTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU43QTV\|IN88UU4>	NInPNJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MKN7	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1Mlc6OTNizszNMi=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H727	NFz1d\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF[4Wm1KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|I4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Nj6wOVE{KM7:TT6=	NIHvU2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H4	MmfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnqzTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMk[uN\|c3QCEQvF2u	MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
647-V	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXTVV5JXUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjZwOEixNUDPxE1w	NILPNHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KM-H2	NX3pdoduT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4WxNmlvcGmkaYTpc44hd2ZiaIXtZY4hU01vSEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI3Njl{NDFOwG0v	NYrOcW95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ABC-1	NGPiOlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MknkTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvOTl5NDFOwG0v	MlLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC1806	MoD2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2fhc2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUiwOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjdwM{SyNkDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ES5	NIPDRWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVz6VY95UW6qaXLpeIlwdiCxZjDoeY1idiCHU{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI4NjR7OUmg{txONg>?	MoDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
C3A	NIDPS5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGM{SSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkeuOVY6PCEQvF2u	NXvQTHFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TE-10	M3L6emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEHURYNKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy54M{W2JO69VS5?	MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
S-117	M4fnemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHMuOTF5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyO{44PTdzIN88UU4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	NFjxUpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXXlVlZHUW6qaXLpeIlwdiCxZjDoeY1idiCWR1LDNXRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkeuPVkxOiEQvF2u	NWK0XlVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1793	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3zTTmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|k{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{OD6zNFc3KM7:TT6=	NUf3e\|M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ES4	NFO5fVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYnSPIFiUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI5Njd\|NUKg{txONg>?	MnnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
AN3-CA	NYPGXVRET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NY\xUVlKUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ6Lki1PVMh\|ryPLh?=	NHL4ZpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NMC-G1	NFeyd4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml64TY5pcWKrdHnvckBw\iCqdX3hckBPVUNvR{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI6NjFzMTFOwG0v	NHXtOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H226	NUXGOIlwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3rzZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ7LkK3NFEh\|ryPLh?=	M3zkV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H522	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1nq[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ7LkizN\|kh\|ryPLh?=	M3;VUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW48	NYDQOHFrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2\GdGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlkvQTJ3MjFOwG0v	NXjVOG5pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OE33	M4Kxd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9GOzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOwMlc6PTRizszNMi=>	M{n4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2228	NFHDc\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NE[xT3BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlIzQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{GuNFM1PCEQvF2u	NYL2ZYRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
D-423MG	MmXpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHvaRmtKdmirYnn0bY9vKG:oIHj1cYFvKERvNEKzUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNzLkC1OlQh\|ryPLh?=	M2mxU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
IST-MEL1	MmnhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2PRVyxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS5zNUK4JO69VS5?	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A388	NUeyPG5WT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M33OcWlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|EvPjJ\|NjFOwG0v	NXPJR5J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LN-405	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1fiXmlvcGmkaYTpc44hd2ZiaIXtZY4hVE5vNEC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS55OUizJO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DMS-273	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlrnTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS57MUO4JO69VS5?	NGPlSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KS-1	NXnzOY9QT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3rm[GlvcGmkaYTpc44hd2ZiaIXtZY4hU1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvOTN{MTFOwG0v	NEDjTVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H209	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoP4TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzNwNEWxO{DPxE1w	NE\odWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HOS	NIrGVGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIm2NHpKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvPzJ3MzFOwG0v	NH\VO\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GI-1	M1vCOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOzMlgxPzFizszNMi=>	MoXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	MlO1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmXYTY5pcWKrdHnvckBw\iCqdX3hckBTTVKILVzDMW1UKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|ND6wN\|E2KM7:TT6=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H526	M331cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFrLTllKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|ND6wO\|Yh\|ryPLh?=	NWXRXWE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RPMI-2650	MnWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGnFPXFKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtNlY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{SuOFM{PCEQvF2u	MnyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KYSE-70	M4jKOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFnLOIhKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtO\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2Lki0NlYh\|ryPLh?=	NHywV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Capan-2	NX71OoV{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFXtcJZKdmirYnn0bY9vKG:oIHj1cYFvKEOjcHHuMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN4LkS2OVIh\|ryPLh?=	MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OVCAR-4	NXy2W292T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVrJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM4NjJzN{[g{txONg>?	NYPSTGt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OVCAR-8	NVnoZ4RrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1r0RmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzdwOUiyN{DPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1355	NFLOS4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{fvXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixN\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|OD6xNFUyKM7:TT6=	MlOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-680N	M1vyPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mlu0TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4NG4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN6LkK0Nlkh\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H2122	NVvqOW06T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkPYTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkOzOlMh\|ryPLh?=	M2HiTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Saos-2	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlzsTY5pcWKrdHnvckBw\iCqdX3hckBU[W:\|LUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM6NjdyNUOg{txONg>?	NUnOWZdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC2157	NXHvU\|RvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoH5TY5pcWKrdHnvckBw\iCqdX3hckBJS0N{MUW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC55N{O0JO69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MljjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mmm1TY5pcWKrdHnvckBw\iCqdX3hckBXVVKFLWLDXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwMkm2NkDPxE1w	NVXWWVhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ETK-1	M4rGPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlnPTY5pcWKrdHnvckBw\iCqdX3hckBGXEtvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFEvPTd3MTFOwG0v	M37Kc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
RCC10RGB	MnLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3\SfWlvcGmkaYTpc44hd2ZiaIXtZY4hWkOFMUDSS2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR{LkCxPEDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KP-N-YS	NFLYNWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmnRTY5pcWKrdHnvckBw\iCqdX3hckBMWC2QLWnTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oi5yNkSxJO69VS5?	NFrFZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
T98G	NITVUWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1HEXmlvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFIvPjd\|MzFOwG0v	NYTKWmV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A431	NEPnWI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MknQTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0OU4yQDNzIN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HDLM-2	M4XzUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWS4OFAzUW6qaXLpeIlwdiCxZjDoeY1idiCKRFzNMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR3LkK2NVch\|ryPLh?=	NXHTWnFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CHP-134	M2fyRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1zM{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ3NjF5N{mg{txONg>?	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	NYrvXZpoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1XhTWlvcGmkaYTpc44hd2ZiaIXtZY4hUi2UVEOtWFMuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNE[uOFQ3OSEQvF2u	NILlNpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1650	NG\JT2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX7VZYVQUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES2MlUyODRizszNMi=>	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	M4D3VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3nScmlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLWDSSWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNE[uOVI3PiEQvF2u	NF\SXm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SJRH30	NXOxcIJVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFfuN4RKdmirYnn0bY9vKG:oIHj1cYFvKFOMUlizNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{e3OUDPxE1w	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SF295	MljaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3uzV2lvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ5NjVzOTFOwG0v	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
YAPC	M2nrOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYjTZYpvUW6qaXLpeIlwdiCxZjDoeY1idiC\QWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QC57NEKg{txONg>?	NH7PbW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EFM-19	M17BbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGDXT\|hKdmirYnn0bY9vKG:oIHj1cYFvKEWITT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDlwNUC4OUDPxE1w	M4XHb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MIAPaCa2	MljMVJJwdGmoZYLheIlwdiCjc4PhfS=>		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzMEBKSzVyPUG0NkBvVS5?	NGjvVmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OFM5QCd-MkO0O\|Q{QDh:L3G+
A375	NEXVR\|NRem:uaX\ldoF1cW:wIHHzd4F6	NIXycmg4OiCq	NVj4WYM5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIV5eHKnc4PpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGxidHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVMyKG6PLh?=	NVXmdXpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
A549	NVLLO3ZOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3LhcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczygTWM2OCB;IEGuO\|Uh\|ryPLh?=	NYrCV\|VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
LoVo	M3jrWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{jzeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczygTWM2OCB;IEKuPFMh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NEO4PEc,OjN2N{SzPFg9N2F-
HCT116	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGD5XIlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{BmgHC{ZYPzbY5oKEuUQWOgS\|E{TCCvdYThcpQtKEmFNUCgQUA{NjFizszNMi=>	NVrldGFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
HeLa-MaTu	M1TkXGZ2dmO2aX;uJIF{e2G7		NXn3eotTUW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKEinTHGtUYFVfSCvYYTjbIVlKHCjaYKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25uIFnDOVAhRSByLkCxOEDPxE1w	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
HepG2	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MonpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDoZZJjd3KrbnegUk1T[XNibYX0ZZRqd25uIFnDOVAhRSByLkCzNkDPxE1w	NHL3W5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkzOCd-Mk[2NVE6OjB:L3G+
COLO205	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn74RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIhiemKxcnnu[{BDWkGIIH31eIF1cW:wLDDJR\|UxKD1iMD6wOlkh\|ryPLh?=	M3fYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkGxPVIxLz5{Nk[xNVkzODxxYU6=
A549	NXG0NmJGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVrITnJ2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIhiemKxcnnu[{BMNVKjczDteZRifGmxbjygTWM2OCB;IEGuO\|Uh\|ryPLh?=	NHPGc3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkzOCd-Mk[2NVE6OjB:L3G+
HCT116	NFfX[pNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3rpdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIhiemKxcnnu[{BMNVKjczDHNVNFKG23dHH0bY9vNCCLQ{WwJF0hOyEQvF2u	NWnrdXRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NVE6OjBpPkK2OlEyQTJyPD;hQi=>
HeLa-MaTu-ADR	MWLGeY5kfGmxbjDhd5NigQ>?		NWq1SYw4UW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKEinTHGtUYFVfS2DRGKgcYF1[2inZDDwZYlzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFVmsheGixc4Doc5J6dGG2aX;uMEBKSzVyIE2gN{44KM7:TT6=	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
SW480	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NEHHXXM4OiCqcoO=	NE\3eI9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOFgxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlQzOiEQvF2u	NVLXWlZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0OFg6OThpPkK3OFQ5QTF6PD;hQi=>
SW620	M1jDeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	M4T2WFczKGi{cx?=	Mn65RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{[yNEBk\WyuczDoZZJjd3KrbnegT3JCWyCJMULWJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	NVvVUXdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
AsPC1	NG\OSJRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MlXtO\|IhcHK\|	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEG\|UFOxJINmdGy\|IHjhdoJwemmwZzDLVmFUKEdzMlSgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wOlQzKM7:TT6=	MnuzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{i5OFAoRjJ6MEO4PVQxRC:jPh?=
BA/F3	MmDqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M3yzUlczKGi{cx?=	NFH1VIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIhiemKxcnnu[{BMWkGVIFexNmQhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEm0NEc,OjhyM{i5OFA9N2F-
SKCO1	NXXudYUxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MXO3NkBpenN?	NI\BbJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLR28yKGOnbHzzJIhiemKxcnnu[{BMWkGVIFexNnYhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE4yOTdizszNMi=>	M2fWOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
COLO205	MnjFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M{XuUFczKGi{cx?=	M{[0T2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU\|IxPSClZXzsd{Bp[XKkb4LpcochSlKDRjDteZRidnRxd3ns[EB1gXCnIFvSRXMwf2muZDD0fZBmKFCLS{PDRUBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODV7IN88UU4>	Mkf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|MUexOFgoRjJ7M{G3NVQ5RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / β-catenin / E-cadherin / Vimentin / Fibronection; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 48 hours, and western blot analysis was performed, with β-actin used as a loading control. pS6(235/236) / pS6(240/244); PubMed: 26137449 Mol Cancer Ther Selumetinib (Sel) in combination with BEZ235 or ZSTK474 inhibits pS6 expression in BRAF-mutant melanoma cell lines that are highly sensitive (NZM3, NZM11, NZM20) or moderately sensitive (NZM6, NZM7, NZM12) to single agent selumetinib. Cells were treated with 500 nM of each compound as indicated for 1 or 24 h. Blots are representative images of two independent determinations. pVEGFR(Y1175) / VEGFR2 / pPDGFRβ(Y751) / pPDGFRβ / pAXL(Y702) / AXL / pMEK / MEK; PubMed: 22500798 Cell Dose-dependent RTK reprogramming in response to AZD6244. Dose-dependent induction of RTK expression and activity in 24h-treated SUM159 cells was determined by western blot. Bak / Bad / Bcl-xl / BimEL / BimL / BimS / PUMA / NOXA ; PubMed: 20885957 PLoS One Human lung cancer cell lines (Calu-6, H2347, and H3122) were treated with 3 µM AZD6244 for 4, 8, 24, 48, and 72 hours. Western blots of Bcl-2 family members after treatment with AZD6244.	26384399 26137449 22500798 20885957
Immunofluorescence	β-catenin; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib in a 3D culture for 48 hours. Immunofluorescence staining was done to detect β-catenin-FITC (fluorescein isothiocyanate), and nuclei were stained with DAPI. Images were taken under 60× magnification. FOXO3a; PubMed: 20885957 PLoS One Subcellular localization of FOXO3a in Calu-6 and H522 cells was detected with immunofluorescence staining after AZD6244 treatment.	26384399 20885957
Growth inhibition assay	Cell viability; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 72 hours, and then cell viability was measured using the WST-1 assay.	26384399

In vivo

AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway. ^[1] AZD6244 could inhibit the tumor growth in HT-29 xenograft, which is a colorectal tumor model carrying a B-Raf mutation, at a dose of 100 mg/kg and the tumor growth inhibition of AZD6244 is better than it of Gemcitabine. ^[3] Otherwise AZD6244 could inhibit HCC xenografts tumor growth, which associated with increased apoptosis and down-regulation of cell cycle regulators, including cyclin D1, Cdc-2, CDK2 and 4, cyclin B1, and c-Myc. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Assay of MEK Kinase Activity: Anti-MEK1 antibody is used to immunoprecipitate MEK1 molecules. MEK kinase activity is measured as the ability of immuno-isolated MEK1 to activate recombinant ERK1 in a coupled assay using MBP as the end point of the assay. Phosphorylated MBP is resolved on a 14% SDS-PAGE gel and vacuum-dried before exposure to X-ray film.
Cell Research: ^[1]	- Collapse Cell lines: Primary HCC cell lines including 2-1318, 4-1318 and 26-1004 cells Concentrations: ~ 10 μM Incubation Time: 24 or 48 hours Method: Cells are seeded at a density of 2.0 × 10⁴. After 48 hours incubation, the cells are rinsed twice with culture media. Cells are treated with various concentrations of AZD6244 for 24 or 48 hours. Cell viability is determined by the 3-(4,5-dimethylthiazol-2y1)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation is assayed using a bromodeoxyuridine kit. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: HCC xenografts in mice homozygous for the SCID (severe combined immunodeficiency) mutation Dosages: 50 or 100mg/kg Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (198.82 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Selumetinib (AZD6244) SDF

Molecular Weight	457.68
Formula	C₁₇H₁₅BrClFN₄O₃
CAS No.	606143-52-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	ARRY-142886
Smiles	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04590235	Not yet recruiting	Drug: Selumetinib	Neurofibromatosis 1\|Neurofibroma Plexiform	AstraZeneca\|Merck Sharp & Dohme Corp.	November 12 2020	Phase 1
NCT03433183	Recruiting	Drug: Selumetinib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors\|Neurofibromatosis 1	Sarcoma Alliance for Research through Collaboration\|United States Department of Defense\|AstraZeneca	October 2 2019	Phase 2
NCT03326388	Recruiting	Drug: Selumetinib	Neurofibromatosis Type 1\|Plexiform Neurofibroma\|Optic Nerve Glioma	Great Ormond Street Hospital for Children NHS Foundation Trust\|AstraZeneca	September 26 2019	Phase 1\|Phase 2
NCT03833427	Active not recruiting	Drug: Selumetinib\|Biological: Pembrolizumab	Advanced/Metastatic Solid Tumors	Merck Sharp & Dohme Corp.	March 18 2019	Phase 1
NCT03745989	Active not recruiting	Drug: MK-8353\|Drug: Selumetinib	Solid Tumors	Merck Sharp & Dohme Corp.	February 22 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How about the solubility of S1008? How to prepare for the solution if I need to do the in vivo experiments?
Answer:
S1008 AZD6244 in vehicle 5% DMSO+30% PEG 300+ddH2O will be a suspension for oral administration. If you want a clear solution for injection, you can dissolve it in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM,
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Features:Does not inhibit c-Raf phosphorylated MEK1.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

Selumetinib (AZD6244)